FDA: More Acne Products Recalled Over Cancer-Causing Chemical—See the Full List Here
The FDA announced the recall of more acne products due to contamination of benzene, a cancer-causing chemical. See the full list here.
La Roche-Posay, Proactiv, Walgreens skin care products voluntarily recalled over potentially cancer-causing chemical
Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to elevated levels of a potentially cancer-causing agent.
L’Oréal recalling acne creams sold at Walmart, Target, and Walgreens due to ‘cancer-causing chemical’
Makeup company L’Oréal has recalled popular brand La Roche-Posay’s acne cream because it may contain benzene, a cancer-causing chemical, according to New York Post. Effaclar Duo Dual-Action Acne Treatment contains benzoyl peroxide, which could have the known carcinogen, according to Valisure, an independent testing lab in Connecticut.
Small Number of Acne Products Recalled for Problematic Levels of Benzene
After new U.S. Food and Drug Administration testing of acne products containing benzoyl peroxide, the agency determined that a small number of products should be recalled for possible benzene contamination,
FDA Recalls Some Acne Treatments Due to Benzene Levels
The Food and Drug Administration said several lots of six products containing benzoyl peroxide are being recalled.
Acne product from popular skin care brand recalled due to potential cancer-causing chemical
The chemical that caused the recall is found in gasoline and tobacco; large amounts of the chemical can cause leukemia.
Popular makeup brand recalls acne treatment for possible cancer-causing ingredient
Makeup company L’Oréal S.A. has issued a recall on its popular acne cream Effaclar Duo due to concern that benzene, a known carcinogen, is in the product. Last year, independent Connecticut testing lab Valisure,
Cancer-causing chemical leads popular company to recall skin product
The recall comes in the wake of concerns over contamination of benzene, news outlet reported. A spokesperson for La Roche-Posay wrote in a statement to cleveland.com and The Plain Dealer that product safety is the company’s highest priority.
Knowridge Science Report2d
This cancer drug may extend lifespan, study finds
Scientists from the University of Auckland have discovered that a cancer drug called alpelisib may help extend lifespan—at ...
Pharmaceutical Technology on MSN22h
Vivace closes $35m in Series D for cancer drug development
Vivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug ...
Innovent Is Said to Consider Licensing Partnership for Cancer Drug
Hong Kong-listed Innovent Biologics Inc. is considering a licensing partnership to develop a cancer drug that’s showing ...
What Vanderbilt-Ingram Cancer Center's 'sci-fi' therapy means for this grateful TN dad
This cancer-patient dad of three young kids is grateful for a "sci-fi" blood treatment advanced by Vanderbilt and oncologist Dr. Olalekan Oluwole.
UH Seidman Cancer Center launches groundbreaking clinical trial using cholesterol drug for HPV-related cancers
Researchers are investigating whether a common cholesterol drug could be repurposed to treat HPV-positive cervical cancer.
New Atlas4d
Cancer drug realized after researcher's chance exposure to malaria drug
When experienced researcher Renato Aguilera happened across the chemical structure of a tried-and-true antimalarial drug one ...
BioPharma Dive2d
Arvinas gets positive breast cancer data, but finds differentiation a hard sell
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
Pfizer, Arvinas post mixed late-stage trial results for breast cancer therapy (update)
Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...
Triple-Negative Breast Cancer (TNBC): Understanding Diagnosis and Treatment
TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.
STAT1d
Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein’s lab
A new biotech is raising money to develop a drug believed to be capable of starving cancer cells, based on research out of a ...